

Self-Monitoring Blood Glucose Test Systems for Over-the- Counter Use

Draft Guidance for Industry and Food and Drug Administration Staff

DRAFT GUIDANCE

**This guidance document is being distributed for comment purposes only.
Document issued on: January 7, 2014**

You should submit comments and suggestions regarding this draft document within 120 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to <http://www.regulations.gov>. Identify all comments with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions regarding this document, contact Patricia Bernhardt at patricia.bernhardt@fda.hhs.gov, or at 301-796-6136.



U.S. Department of Health and Human Services
Food and Drug Administration
Center for Devices and Radiological Health
Office of In Vitro Diagnostic Device Evaluation and Radiological
Health
Division of Chemistry and Toxicology Devices

Preface

Additional Copies

Additional copies are available from the Internet. You may also send an e-mail request to dsmica@fda.hhs.gov to receive an electronic copy of the guidance or send a fax request to 301-847-8149 to receive a hard copy. Please use the document number 1756 to identify the guidance you are requesting.

Table of Contents

I.	INTRODUCTION	4
II.	BACKGROUND	4
III.	SCOPE	2
IV.	REDUCING THE RISK OF BLOODBORNE PATHOGEN TRANSMISSION IN DIABETES CARE 3	
A.	VALIDATED CLEANING AND DISINFECTION PROCEDURES	4
B.	DEMONSTRATION THAT THE DEVICE IS ROBUST TO CLEANING AND DISINFECTION PROCEDURES.....	5
V.	DEVICE DESCRIPTION	6
VI.	PERFORMANCE EVALUATION AND CRITERIA FOR SMBG DEVICES	7
A.	PRECISION EVALUATION STUDY	7
B.	LINEARITY EVALUATION STUDY.....	9
C.	METHOD COMPARISON/USER EVALUATION	9
1.	<i>General Study Design:</i>	9
2.	<i>Data Analyses:</i>	12
D.	INTERFERENCE EVALUATION.....	14
1.	<i>Endogenous/Exogenous Substances</i>	14
2.	<i>Hematocrit</i>	17
E.	FLEX STUDIES	19
1.	<i>Test Strip Stability Testing</i>	21
2.	<i>Temperature and Humidity Effects on SMBG Device</i>	22
3.	<i>Altitude Effects</i>	23
4.	<i>Short Sample Detection</i>	23
5.	<i>Sample Perturbation Study</i>	23
6.	<i>Intermittent Sampling</i>	24
7.	<i>Testing with Used Test Strips</i>	24
F.	CALIBRATION AND EXTERNAL CONTROL MATERIALS	24
VII.	TEST STRIP LOT RELEASE CRITERIA	25
VIII.	SOFTWARE	26
IX.	LABELING	26
	APPENDIX 1. POTENTIAL SOURCES OF ERROR TO CONSIDER FOR SMBG DEVICES	34
	APPENDIX 2. SPECIAL 510(K)S AND SMBG DEVICES	37

Self-Monitoring Blood Glucose Test Systems for Over-the-Counter Use:

Draft Guidance for Industry and Food and Drug Administration Staff

This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance.

I. Introduction

This draft guidance document describes studies and criteria that FDA recommends be used when submitting premarket notifications (510(k)s) for self-monitoring blood glucose test systems (SMBGs) which are for over-the-counter (OTC) use by lay-persons. When finalized, FDA intends for this document to guide manufacturers in conducting appropriate performance studies and preparing premarket notifications for these device types.

This guidance is not meant to address blood glucose monitoring test systems which are intended for prescription point-of-care use (e.g., hospitals, physician offices, long term care facilities, etc.). FDA is issuing another draft guidance entitled “Blood Glucose Monitoring Test Systems for Prescription Point-of-Care Use” to address those device types.

FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

II. Background

Contains Nonbinding Recommendations
Draft - Not for Implementation

22 Portable blood glucose monitoring systems (also called glucose meters) that measure blood
23 glucose concentrations are used by millions of people with diabetes every day. These devices
24 are used by patients in a variety of settings including in their homes, at work, and in schools.

25
26 Historically, the FDA has not recommended different types of information in premarket
27 submissions (510(k)s) for blood glucose monitoring systems used by medical professionals as
28 compared to OTC devices intended for use by lay users. However, it has become
29 increasingly clear that these different use settings create distinct intended use populations
30 with unique characteristics and device design requirements. For example, medical
31 professionals are generally more proficient at performing testing and at running appropriate
32 controls, and they typically have a better understanding of test limitations as compared to lay-
33 persons. Further, the term “lay-person” encompasses a group of individuals with wide ranges
34 in age, dexterity, vision, training received on performing testing, and other factors that can be
35 critical in the patient’s ability to accurately use the device and interpret test results.

36
37 SMBG devices and the associated test strips used by lay-persons are also more likely to
38 undergo more varied storage and handling conditions compared to devices used in
39 professional settings. As such, these devices should be designed to be more robust and
40 reliable to accommodate actual use conditions.

41
42 In order to distinguish between prescription use blood glucose meters, which are intended for
43 use in point-of-care professional healthcare settings, and those intended for OTC self-
44 monitoring by lay-persons, the Agency is issuing two separate draft guidances for (i)
45 prescription use blood glucose meters, for use in point-of-care professional healthcare
46 settings, and (ii) SMBG devices intended for OTC self-monitoring by lay-persons. The FDA
47 believes that in making this distinction, SMBG devices can be better designed to meet the
48 needs of their intended use populations, thereby ensuring greater safety and efficacy.

49
50 In recent years, concerns have been raised citing infection control issues related to glucose
51 meters and the lancet device. According to the Centers for Medicare and Medicaid Services
52 (CMS) and the Centers for Disease Control and Prevention (CDC), blood glucose monitoring
53 devices (meters and lancing devices) can transmit bloodborne pathogens if these devices are
54 contaminated with blood specimens and are shared between users without effective cleaning,
55 disinfecting and appropriate infection control measures. Though SMBG devices are intended
56 for home use, they should also be designed to withstand appropriate cleaning and disinfection
57 procedures over the life of these devices. These disinfection procedures should be properly
58 validated (see Section IV below) for this type of device and appropriate instructions provided
59 for the user. Validation methods should take into account the way in which the device is
60 used, e.g., by lay users at home (or in other non-professional settings).

62 **III. Scope**

63
64 This draft guidance document is limited to SMBGs, which are regulated under 21 CFR
65 862.1345, Glucose Test System. The product code NBW applies to SMBGs.

66

67 This document is **not** meant to address the following types of devices:

- 68 • Blood glucose monitoring test systems intended for use in prescription point-of-care
69 settings (e.g., hospitals, physician offices, long term care facilities, etc.)
- 70 • Devices used to screen and diagnose diabetes (such as clinical chemistry analyzers or
71 semi-quantitative strips).
- 72 • Implanted or continuous glucose sensors.
- 73 • Non-invasive glucose measurement devices, (i.e., devices that do not require removal
74 of a blood sample from a fingerstick or other anatomical site).
- 75 • Devices for measurement of blood glucose in neonates.

76

77 The device types addressed in this document typically use capillary whole blood from
78 fingersticks or alternative anatomical sites. This device is not intended for use in healthcare
79 or assisted-use settings such as hospitals, physician's offices, or long-term care facilities
80 because it has not been determined to be safe and effective for use in these settings, including
81 for routine assisted testing or as part of glycemic control procedures. Use of this device on
82 multiple patients may lead to transmission of Human Immunodeficiency Virus (HIV),
83 Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), or other bloodborne pathogens.

84

85 We recommend that you contact the Division of Chemistry and Toxicology Devices in the
86 Office of In Vitro Diagnostics and Radiological Health if you have questions regarding
87 alternate intended uses of your device.

88

89 **IV. Reducing the Risk of Bloodborne Pathogen** 90 **Transmission in Diabetes Care**

91

92 Because SMBG devices use blood specimens for glucose measurement, their design and
93 instructions for use are very important factors in reducing the risk of bloodborne pathogen
94 transmission during use. According to the Centers for Medicare and Medicaid Services
95 (CMS) and the Centers for Disease Control and Prevention (CDC), blood glucose monitoring
96 devices, as well as blood lancet devices, can transmit bloodborne pathogens such as viral
97 hepatitis if these devices are contaminated with blood specimens and are shared between
98 users without effective cleaning and disinfection. You should address the following
99 considerations for device design and labeling:

100

- 101 • All SMBG devices should be intended for single patient use. The intended use
102 should clearly state that the SMBG device is intended for use by lay users and should
103 only be used for a single user.
- 104 • Meters should be designed such that all external materials can be cleaned (removal of
105 organic soil) and disinfected (microbicidal process).
- 106 • All external surfaces of the meter, including seams and test strip port, should be
107 designed for both ease of use and ease of cleaning and disinfection.

Contains Nonbinding Recommendations
Draft - Not for Implementation

- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- You should develop an effective disinfection method that can be easily employed by lay users at home. You should provide the validated cleaning and disinfecting procedures for your SMBG device in your submission as well as in the labeling. Cleaning and disinfection are different processes and need separate validation procedures and specifications. See Sections IV.A and B. below for details on the recommended cleaning and disinfecting validation studies.
 - You should validate the use of any disinfectant you recommend for use with your device, as described in more detail below. We recommend you consult the Environmental Protection Agency’s (EPA) list of disinfectants that are registered for use against infectious bacteria and viruses¹ when choosing disinfectants to validate for use with your device.
 - You should clearly warn users that lancing devices are for single-patient use only and should NEVER be shared.
 - Labeling concerning safe device use can reduce the risk of user error; therefore, instructions for cleaning and disinfection should be clear and detailed. Labeling for all test system components should incorporate the same proprietary device name (ABC blood glucose test system, ABC blood glucose meter, ABC blood glucose test strips, etc.). See Section IX, Labeling below for detailed labeling recommendations.

127 Validation of cleaning and disinfection procedures involves both validation that the cleaning
128 and disinfection products are effective against the primary viruses of concern (HIV, Hepatitis
129 B, Hepatitis C) and validation that the cleaning and disinfection procedures do not deteriorate
130 the device or alter device performance. FDA recommendations for such validation are
131 outlined in the following sub-sections.

132

133 ***A. Validated cleaning and disinfection procedures***

134 You should select cleaning and disinfection products that do not result in physical
135 deterioration of the device overall, or any device component, such as the housing, touch
136 pad, or buttons. You should make note of these physical indicators during your
137 validation study and provide this information in your 510(k). The disinfectant product
138 you choose should be effective against HIV, Hepatitis C, and Hepatitis B viruses.
139 Outbreak episodes associated with glucose monitors have been primarily due to
140 transmission of Hepatitis B viruses. Please note that 70% ethanol solutions are not
141 effective against viral bloodborne pathogens, and the use of 10% bleach solutions may
142 lead to physical degradation of your device.

143

144 To demonstrate that your disinfection protocol is effective against Hepatitis B virus you
145 should perform disinfection efficacy studies to demonstrate that your procedure is
146 effective with the external meter materials. Studies have demonstrated that viruses can
147 remain infective for different time periods, depending on the surface. Viral survival may
148 increase or decrease with the number of microbes present on a surface. Increasing

¹. Selected EPA-registered Disinfectants <http://www.epa.gov/oppad001/chemregindex.htm>

149 amounts of microbes can protect viruses from disinfection, but damaging effects may also
150 result from microbial proteases and fungal enzymes. Factors that influence survival on
151 surfaces include fomite properties, initial viral titer, virus strain, temperature, humidity
152 and suspending media. The simplest disinfection method would be the use of towelettes
153 pre-saturated with a selected disinfectant. Disinfection with a towelette will reduce the
154 risk of liquid getting into the meter device, therefore minimizing the chance of affecting
155 the glucose meter reading. However, you should choose a disinfectant that is effective
156 (against Hepatitis B Virus) and compatible with your specific device. In addition, you
157 should choose a disinfection method that uses products that would be readily available to
158 the home user.

159
160 We recommend you refer to the following standards:

- 161 • ASTM standard E1053-97(Reapproved 2002), Standard Test Method for Efficacy
162 of Virucidal Agents Intended for Inanimate Environmental Surfaces
- 163
- 164 • ASTM standard E23620-09, Standard Practice for Evaluation of Pre-saturated or
165 Impregnated Towelettes for Hard Surface Disinfection.
- 166

167 ***B. Demonstration that the device is robust to cleaning and disinfection*** 168 ***procedures***

169 You should demonstrate through bench studies that your SMBG device is robust to
170 cleaning and disinfection procedures after multiple cleaning and disinfection cycles. You
171 should describe in your submission the study design and results demonstrating that the
172 analytical performance of the blood glucose monitoring system is not impacted by the
173 cleaning and disinfection procedures.

174
175 You should address the following in designing your study:

- 177 • You should choose worst case scenarios with regard to cleaning and disinfection
178 frequency and end user environment to determine the number of cleaning and
179 disinfection cycles that should be tested. For example, the number of times you
180 clean and disinfect the meter should be representative of the cleaning and
181 disinfection that the meter will be exposed to in its use life (typically 3-5 years).
- 182 • We recommend using the same disinfectant product for both cleaning and
183 disinfection. The effects of multiple products on the efficacy of the disinfectant
184 products are not well understood.
- 185 • You should demonstrate that the test strip port and all other openings are able to
186 withstand your recommended cleaning and disinfection procedures. The test strip
187 port and material seams are highly susceptible to blood contamination, therefore it
188 is important to be able to clean and disinfect these portions of your meter to
189 reduce the risk of bloodborne pathogen transmission.
- 190 • When you evaluate your device after the cleaning and disinfection phase you
191 should ensure that the procedure does not cloud the face/display of the meter and
192 does not corrode or erode the plastic housing or buttons. You should note all

193 these physical indicators throughout your study and include these results in your
194 submission. You should evaluate the performance of the meter to ensure that
195 repeated cleaning and disinfection does not affect performance (accuracy). You
196 should also demonstrate that lifetime cleaning and disinfection of any re-useable
197 lancing devices packaged or recommended for use with your meter does not affect
198 its performance or exterior materials.

- 199 • You should include infection control in your risk analysis studies and incorporate
200 your validated cleaning and disinfecting procedures into your risk assessment.

201
202 You should incorporate your labeling instructions for cleaning and disinfection in your
203 user study (see Section VI-C, below) to determine the effectiveness and clarity of the
204 instructions in your labeling for lay users.
205

206 **V. Device Description**

207
208 You should provide a general description of the SMBG device in your 510(k). Typically,
209 much of this information is also included in the User Manual; however, some of the
210 information is not appropriate for the intended user (e.g., highly technical explanations) and
211 should be included in the 510(k) only. You should provide the following in the 510(k):
212

213 General device description:

- 214
215 • Physical components of the system (including diagrams where appropriate).
- 216 • Manufacturer's performance specifications.
- 217 • Description and explanation of the test principle, including chemical reactions.
- 218 • Description of the format of results, including units of measure and whether results
219 are reported in whole blood or plasma equivalents².
- 220 • Description of the composition and levels of control material.
- 221 • User maintenance needs (e.g., batteries).
- 222 • Features of the device, such as data transmission capabilities or features designed to
223 enhance robustness, including ease of use.
- 224 • Features designed to minimize the risk of bloodborne pathogen transmission among
225 patients.

226
227 Description of features controlled by the software:

- 228
229 • Displays and user messages: This includes how the system determines and displays
230 the glucose concentration; messages or displays that appear while a user is taking a
231 measurement; and features such as how a user can retrieve past results from storage in

² Note that for SMBG devices intended for use in the U.S., plasma equivalent results should generally be reported.

232 the device.

233

- 234 • Error messages: This includes any error messages that the SMBG displays.
235 Examples include displays or messages that the user sees when a strip is inserted
236 incorrectly or removed prematurely; too small a sample is applied to the test strip; or
237 damaged, incorrect or deteriorated strips are used. You should also describe the error
238 tolerance for user actions, such as these, that are inconsistent with device operation.
239
- 240 • User prompts: You should describe prompts that the device provides to the user,
241 expected user responses, and timing issues (e.g., how quickly does the user need to
242 respond, what happens if they respond after the allowed time). Examples of a user
243 prompt are messages to the user to insert the test strip into the meter, add blood
244 sample to the test strip, calibrate the meter, or store a result in memory.
245
- 246 • Alarms and other feedback: You should describe how the system responds to errors in
247 user action, user inaction, or system status, e.g., low batteries or high ambient
248 temperature. This includes methods by which the system detects and alerts the user
249 when glucose levels are outside of the linear range of the system. Further, you should
250 explain any self-diagnostic routines that the system performs.

251

252 It is important that you identify the expected responses by the user to messages. This
253 includes whether and how the user should input information or press certain buttons to
254 correctly set up the meter or to respond to a message.

255

256 **VI. Performance Evaluation and Criteria for SMBG** 257 **Devices**

258

259 Sections A-F below indicate the types of device performance information that you should
260 include in a 510(k) submission for a SMBG device.

261

262 In this section, the term “reference method” refers to a laboratory-based glucose measurement
263 method that has been well-validated for precision and accuracy, and that is traceable to a
264 higher order, e.g., internationally recognized, reference material and/or method. The
265 traceability chain should include as few stages as possible to reduce bias. FDA’s current
266 thinking on the issues that should be addressed and the recommended study designs and
267 device performance evaluations are discussed below in Sections A-F.

268

269 **A. Precision Evaluation Study**

270 You should evaluate both repeatability and intermediate precision for your SMBG. The
271 following sections outline FDA’s current thinking on appropriate study design and
272 analyses to evaluate repeatability and intermediate precision for SMBG devices.

273

Measurement Repeatability Evaluation:

In order to assess imprecision of the device across the claimed measuring range, you should evaluate samples containing the following five glucose concentration intervals provided in the table below:

Table 1. Glucose Concentrations for Repeatability Evaluation

Interval	Glucose Concentration Range (mg/dL)
1	30-50
2	51-110
3	111-150
4	151-250
5	251-400

You should determine repeatability using venous blood samples. Altered venous blood samples such as those that are spiked, diluted, or allowed to glycolyze in order to obtain the appropriate glucose concentrations are acceptable to facilitate coverage of the entire glucose concentration range using the concentration intervals outlined in Table 1. However, you should clearly identify all altered samples (spiked, diluted, or glycolyzed) in all submitted data. A minimum of 500 test strips from at least 10 vials and 3 manufacturing lots should be used in the study. For each sample concentration, a minimum of 10 meters should be used for these studies, with at least 10 measurements taken by each meter (i.e., 100 measurements per concentration). These tests strips should be taken from the same vial and/or package for each meter.

We recommend you present the results as the mean value of the 10 measurements per meter with the corresponding standard deviation (SD) and percent coefficient of variation (CV). For each glucose concentration range in Table 1, you should also provide the mean value, standard deviation (with 95% confidence intervals) and percent CV for data combined over all meters. You should describe the statistical procedures used in the analysis. You should also include a summary of any identified outliers that were excluded from statistical analysis, the method of outlier identification and the results of these outlier investigations.

Intermediate Precision Evaluation:

Intermediate precision measurement studies are designed to measure imprecision under normal conditions of use by the intended user (i.e., measurement by individuals over multiple days, with the same meter, and reagent system lot). These studies should be performed with prepared materials, such as control materials for use with the SMBG device.

The total number of meters and individual users in these studies is at the discretion of the sponsor, however a minimum of 10 devices should be used for each concentration. Precision should be evaluated over a minimum of 10 days, taking at least 1 measurement

312 per day of a sample from each glucose concentration interval listed in Table 1, for a
313 minimum of 10 measurements per meter for each concentration (and 100 measurements
314 per concentration). You should use a minimum of 500 test strips from a minimum of 10
315 vials or packages and 3 manufacturing lots. These tests strips should be taken from the
316 same vial and/or package for each meter. The study should demonstrate acceptable
317 precision for all lots, users and meters.

318

319 You should present data including the mean value of the measurements per meter with
320 the corresponding standard deviation (SD) and percent coefficient of variation (CV). For
321 each glucose concentration in Table 1 you should also present the mean value, standard
322 deviation (with 95% confidence intervals) and percent CV for data combined over all
323 meters. You should describe the statistical procedures you use. You should provide
324 results based on all data. If any outliers were excluded from any of your statistical
325 analyses, you should fully describe the method of outlier identification and the results of
326 these outlier investigations.

327

328 ***B. Linearity Evaluation Study***

329 You should evaluate the linearity of your device across the entire claimed measuring
330 range. We recommend that studies include an evaluation of at least 11 evenly spaced
331 concentrations tested and analyzed according to “Evaluation of the Linearity of
332 Quantitative Measurement Procedures: A Statistical Approach”, CLSI document EP6-A.
333 Linearity studies should be performed using venous blood samples. Altered venous blood
334 samples such as those that are spiked, diluted, or glycolyzed are acceptable to facilitate
335 coverage of the entire glucose concentration range. You should clearly identify all altered
336 samples (spiked, diluted, or glycolyzed) within the submitted data.

337

338 You should submit a detailed description of the study design, target concentrations, a list
339 of all data collected in this study, summary of the results and conclusions drawn from the
340 study, and a description of the statistical analysis used.

341

342 ***C. Method Comparison/User Evaluation***

343

344 **1. General Study Design:**

345 We recommend that you design a single evaluation to assess both system accuracy in the
346 hands of the intended users, as well as other aspects to support lay use, such as labeling
347 assessment and usability. This type of design will more accurately reflect the device
348 performance in the hands of the intended user, therefore providing a better estimate for
349 total accuracy of the SMBG device.

350

351 FDA recognizes that most study evaluations performed for pre-market submissions occur
352 in idealized conditions, thereby potentially overestimating the total accuracy of the
353 SMBG device, even when performed in the hands of the intended user. It is important to
354 design your study to most accurately evaluate how the device will perform in the hands of

Contains Nonbinding Recommendations
Draft - Not for Implementation

355 the intended use population. Therefore, the study should be conducted under conditions
356 that reflect the expected use of the device by the intended use population. These
357 conditions should be consistent with the validated environmental conditions of the device
358 (e.g., temperature, humidity, altitude etc.). You should fully describe the conditions of
359 your study in your pre-market submission.

360

361 You should include at least 350 different subjects in your method comparison study.
362 Fresh capillary samples should be obtained with sufficient volume to be measured on
363 both the candidate device and the reference method. If you are planning to include claims
364 that your device can be used at alternative sites (e.g., forearm, palm, etc.), you should
365 obtain and evaluate 350 samples from each site.

366

367 For each claimed anatomical site the samples should adequately span the claimed
368 measuring range of the SMBG device. Though it may be difficult to obtain samples at
369 the extreme ends of the measuring range, the study should contain at least 10 unaltered
370 samples with blood glucose concentrations < 80 mg/dL, and at least 10 unaltered samples
371 between 250 mg/dL glucose and the upper limit of the claimed measuring range of the
372 device. If these ranges are not covered after collecting samples from 350 subjects (for
373 each sample site), additional subjects should be enrolled until adequate sample
374 concentrations are collected. Data from all subjects in the study should be submitted, and
375 no subjects should be excluded from the data analysis.

376

377 The subjects you enroll in the method comparison/user study should accurately reflect the
378 intended use population of the device. The study group should be comprised of both naïve
379 and non-naïve SMBG users. At least 10% of the study participants should be naïve to
380 SMBG devices. You should describe the inclusion and exclusion criteria for enrolling the
381 study participants, as well as the demographic characteristics of the subjects that
382 participated in the study.

383

384 Prior to testing, study subjects should be given the device labeling (instructions for use,
385 user manual etc...) that will be provided to the user with the device once on the market.
386 For purposes of the study these instructions for use should be written in English only;
387 translations into other languages should not be provided to these study participants.
388 Prior to the study, you should perform a readability assessment (in terms of grade level)
389 of the user manual, test strip insert, and control solution insert. For an over-the-counter
390 product the reading level should be at an 8th grade level or less. We recommend using
391 the Flesch-Kincaid, SMOG, or equivalent computer program to assess the readability
392 grade level of the labeling. You should describe the assessment and results in your
393 submission.

394

395 The study subjects should obtain their own capillary sample and perform a blood glucose
396 test using only the device labeling as instructions. No other training or prompting should
397 be provided to the user, and they should not receive assistance from a study technician or
398 healthcare provider to obtain the test result. Study subjects should be sequestered in such
399 a way so they can not observe or be influenced by the testing technique of other study

Contains Nonbinding Recommendations
Draft - Not for Implementation

400 participants or technicians. Once the study participant has obtained their own result using
401 the SMBG device, the technician should then obtain an additional capillary sample for
402 testing on the reference method. Since the intended user population of SMBG devices is
403 the lay-person, it is not necessary for the technician to obtain capillary results on the
404 SMBG device for comparison to the reference value.

405
406 You should include a minimum of 3 test strip lots and a minimum of 10 test strip vials or
407 packages in the study. All test strips used in the study should have undergone typical
408 shipping and handling conditions from the site of manufacture to a U.S. user prior to
409 being used in the study. You should describe these shipping and handling conditions in
410 your premarket submission.

411
412 Hematocrit values should be determined and recorded for each of the study participants.
413 You should present individual hematocrit values in the 510(k) along with the meter
414 results.

415
416 Blood glucose test results are used by people with diabetes to make critical decisions
417 about their treatment; therefore, it is important that the results are accurate so that
418 nutritional and drug dosing errors are better avoided. In order to demonstrate that your
419 SMBG device is sufficiently accurate to be used safely by diabetic patients for this
420 purpose, you should demonstrate that 95% of all SMBG results in this study are within
421 +/- 15% of the reference measurement across the entire claimed measuring range of the
422 device and that 99% of all SMBG results are within +/- 20% of the reference
423 measurement across the entire claimed measuring range of the device. You should
424 include all results in the submission. If there are any SMBG test results that are >20%
425 relative to the reference, you should provide a justification for why the errors occurred
426 and describe why the potential for that error does not render the device unsafe and
427 ineffective, even when extrapolated to the intended use setting (e.g., when billions of tests
428 are performed). We will review the justification to determine whether the data suggests
429 that patients may be put at risk, or whether the sponsor's justification and proposed
430 mitigation would be adequate.

431
432 FDA understands that some SMBG devices may not be able to measure reliably within
433 15% of the reference method at very low concentrations. If this is the case, you may need
434 to raise the lower end of the claimed measuring range to the concentration where your
435 device is sufficiently accurate according to the above described criteria. We expect that
436 to meet the clinical needs of the user population, SMBG devices should minimally be
437 able to measure blood glucose accurately down to 50 mg/dL and up to 400 mg/dL. The
438 SMBG device should identify and provide an error code in situations where the measured
439 glucose falls outside of the device's stated measuring range. For example, meter XYZ
440 has a measuring range that can detect glucose concentrations down to 50 mg/dL;
441 therefore, blood samples with glucose concentrations below 50 mg/dL should provide an
442 appropriate error code (e.g., "LOW - Less than 50").

Contains Nonbinding Recommendations
Draft - Not for Implementation

444 Method comparison and user performance studies for SMBG systems include multiple
445 users and multiple blood glucose monitoring devices. Individual lancing devices should
446 be used for each subject. The protocol for these studies should include measures in place
447 to mitigate the risk of potentially transmitting disease between healthcare providers,
448 subjects and users (for example use of disposable gloves or other physical barriers). The
449 study protocol should also include details on how often and when gloves of the trained
450 health professionals should be changed between users. Refer to Section IV above
451 (Reducing the Risk of Bloodborne Pathogen Transmission in Diabetes Care) for
452 additional information regarding the validation of cleaning and disinfecting of SMBG
453 devices. You should describe these aspects of the protocol in your 510(k).

454
455 You should also describe the following in your 510(k):

- 456
457 • Study setting (i.e. description of the type of study location and operators used for
458 the study and a justification of how the selected study conditions simulate
459 intended use conditions).
- 460 • Type of study participants and the inclusion and exclusion criteria used to select
461 the participants.
- 462 • Patient demographics (age range, education level, native language, work
463 experience, disease state) and whether they are naïve SMBG device users or not.
- 464 • Details of procedures performed by lay users and study technicians.
- 465 • Instructions provided to users in the study. (Note: All instructions must be
466 provided to users in English only.)
- 467 • Type of sample collected (anatomical collection site(s)).
- 468 • Number of test strip lots, number of test strip vials, and number of meters used in
469 the study.
- 470 • Description of the shipping and handling conditions of the test strips prior to use
471 in the study.
- 472 • A user questionnaire should be provided for the study participants to fill out after
473 completing the study. A copy of the questionnaire and the results should be
474 provided in the submission.

475
476 **2. Data Analyses:**

477 You should present all data in the submission, including cases in which the meter
478 displays an error code, a ‘High’ or ‘Low’ message, or no result. All outliers that do not
479 conform to the minimum accuracy criteria should also be included. All such outlier
480 results should be investigated and explained when possible. To assist in this
481 investigation, you should collect information regarding patient medications, hematocrit
482 measurements, disease states during your study. You should include the following in
483 your description of the results:

484
485 *Regression analysis:*

Contains Nonbinding Recommendations
Draft - Not for Implementation

486 You should present the difference between individual study subject results and the
487 reference value (or mean of the reference value, if multiple replicates are measured on the
488 reference method) by plotting the candidate SMBG device as the dependent variable and
489 the reference value as the independent variable. The plot should include the regression
490 line and line of identity, as well as the 95% and 99% confidence intervals. Your
491 summary of results should include the slope and y-intercept, calculated using suitable
492 regression analysis procedures, and the estimate of the deviation such as the standard
493 error (*S_{yx}*). You should describe all statistical methods used and clearly identify and
494 describe any outliers in the analysis.

495

496 *Tabular data presentation:*

497 In addition to providing the results of regression analysis, you should also present results
498 in the following tabular format for each sample matrix. In this table, X= the number of
499 samples within the specified difference from the reference method, and Y= total number
500 of samples.

501

502 **Table 2. Summary of data within specified mg/dL of the reference method:**

503 For glucose concentrations across the entire range:

Within +/- 5 mg/dL	Within +/- 7 mg/dL	Within +/- 10 mg/dL	Within +/- 15 mg/dL
X/Y (%)	X/Y (%)	X/Y (%)	X/Y (%)

504

505

506 *Accuracy at Extreme Glucose Values*

507 Because the user study may not provide a sufficient evaluation of the device performance
508 in the extreme upper and lower ends of the measuring range, you should perform
509 additional studies using blood samples altered to less than 80 mg/dL and greater than 250
510 mg/dL. These samples should mimic unaltered patient samples as closely as possible.
511 These additional studies should be performed separately from the above mentioned
512 method comparison/user performance evaluation (Section VI.C) and may be performed in
513 a laboratory setting (e.g., at the manufacturer's facility).

514

515 Capillary whole blood samples should be used for these studies. You should include a
516 minimum of 50 prepared samples containing glucose concentrations below 80 mg/dL and
517 50 samples greater than 250 mg/dL. These samples should evenly cover the lower and
518 upper limits of the claimed measuring range. Samples may be altered by spiking or
519 allowing the samples to glycolyze in order to obtain the appropriate glucose
520 concentrations. Samples should be measured on both the SMBG device and the reference
521 method. You should analyze the data using the same methods described above for the
522 user evaluation studies. FDA will also apply the same review criteria.

523

524 *Error Codes for Samples Outside the Measuring Range:*

525 You should demonstrate in your premarket submission that your device provided the
526 appropriate error codes when glucose concentrations were out of the device's stated
527 measuring range.

528

529 **D. Interference Evaluation**

530 You should evaluate the effect of potentially interfering endogenous and exogenous
531 substances and conditions on device performance. This includes icterus, lipemia, and
532 varying hematocrit levels, as well as the effect of common medications.

533

534 **1. Endogenous/Exogenous Substances**

535 *Study design:*

536 You should perform interference testing using samples containing glucose concentrations
537 across the range of the device. Specifically, testing should be performed in samples with
538 glucose concentrations of 60 mg/dL, 120 mg/dL, and 250 mg/dL to evaluate clinically
539 relevant decision points.

540

541 You should evaluate each potentially interfering substance at clinically relevant
542 concentrations. You should test all substances at a minimum of two concentrations – the
543 concentration that is expected or the therapeutic concentration, and the concentration that
544 is the highest that could potentially be observed in a whole blood sample. For example,
545 acetaminophen should be tested at the expected therapeutic concentration 20 µg/mL and
546 also at the high, toxic concentration 200 µg/mL. Table 3 below lists our
547 recommendations on the substances and concentrations that should be tested for
548 interference. Table 4 below provides a sample format.

549

550

Table 3. List of Potential Interferents for SMBG Devices

Interferent	Therapeutic Level	High Toxic Concentration
Acetaminophen	20 µg/mL	200 µg/mL
Ascorbic acid	0.8 mg/dL	3 mg/dL
Bilirubin	1 mg/dL	25 mg/dL
Cholesterol	154 mg/dL	309 mg/dL
Creatinine	1 mg/dL	10 mg/dL
Dopamine	20 pg/mL	200 µg/mL
EDTA	0.1 mg/mL	2 mg/mL
Galactose	1 µg/mL	100 µg/mL
Gentisic acid	0.1 mg/mL	10 mg/mL
Glutathione	5 µmol/L	100 µmol/L
Hemoglobin	14 g/dL	20 g/dL
Heparin	0.5 IU/mL	5 IU/mL
Ibuprofen	10 µg/mL	500 µg/mL
L-Dopa	2 µg/mL	5 µg/mL
Maltose	1 mg/mL	100 mg/mL
Methyldopa	10 mg/L	10 g/L
Salicylate	100 µg/mL	500 µg/mL
Sodium	120 mEq/L	175 mEq/L
Tolbutamide	100 mg/L	1000 mg/L

*Contains Nonbinding Recommendations
Draft - Not for Implementation*

Tolazamide	40 mg/L	400 mg/L
Triglycerides	100 mg/dL	500 mg/dL
Uric acid	5 mg/dL	10 mg/dL
Xylose	20 mg/dL	200 mg/dL
Sugar Alcohols*	0.03 mg/100mL	0.09 mg/100mL

*All common sugar alcohols should be tested including mannitol, sorbitol, xylitol, lactitol, isomalt, maltitol and hydrogenated starch hydrolysates (HSH). Sponsors should determine appropriate levels to test for interference with SMBG devices based upon common concentrations of these substances in the blood of diabetic patients.

You should provide a reliable estimate of the interference predicted for individual samples. To do this, we recommend the following method of measuring and calculating interference: Each sample should be tested on the reference method in replicates (minimum of 4). An average of reference measurements, for example, may give greater confidence in the true glucose concentration of the sample. You should use at least 3 test strip lots to evaluate interference. Each test sample should be tested on the new SMBG device in replicates of 30 (10 replicates per lot of test strips, for a total of 30 replicates per sample). Each replicate should be compared to the average value obtained from the reference method and a bias and % bias calculated. The % bias for each replicate should be combined to produce an average % bias for the sample (with 95% confidence intervals).

In the rare case where the substance being evaluated for interference with the new device also interferes with the reference method, a reference sample should also be created for each substance that contains the identical glucose concentration but solvent/vehicle in lieu of the potential interfering substance. The test sample can then be compared to the reference sample value as measured by the reference method. You should provide information demonstrating interference with the reference method for each substance in this category.

For SMBG devices intended for lay use, the degree of acceptable interference may vary by substance tested. For example, a small interference at extremely high acetaminophen concentrations may be able to be communicated through labeling because users are aware that they have or have not taken that drug. Other potential risks, e.g., observed interference from uric acid, may be more difficult to mitigate through labeling because the user may be unaware of their condition or incapable of determining at home whether they may be at risk. Therefore, you should report in the 510(k) the observed average percent bias for each sample/substance tested and any observed trends. If interferences are observed, then you should propose appropriate labeling to mitigate the risk of the interference in the lay user population; the labeling language appropriate for the observed interference will be discussed during the review of the submission. We do not recommend that final labeling be printed prior to receiving FDA input during the review.

If significant interference is observed at one substance concentration but not the other, you should perform additional analyses to determine the concentration at which interference begins to occur. For example, if a bias of 12% is observed at 200 µg/mL

Contains Nonbinding Recommendations
Draft - Not for Implementation

592 dopamine and no significant bias is observed at dopamine concentrations of 20 pg/mL,
593 additional testing should be performed to determine the lowest concentration between 20
594 pg/mL and 200 µg/mL where interference is first observed. In the 510(k), you should
595 provide your definition of “significant” interference for that substance.

596

597 The substances listed above in Table 3 represent known or reasonable potential
598 interferents for current glucose measurement technologies. As new drugs are developed
599 or new interfering substances are identified, you should evaluate them for potential
600 interference with your device. For example, if a new drug intended to treat cardiac
601 complications in diabetic patients is approved, you should conduct a robust evaluation to
602 determine whether the new drug interferes with your device. You should report to FDA if
603 significant new interferences are observed with any cleared glucose monitoring device
604 that is on the market. You should also evaluate new drugs/potential interferents when
605 new or significantly modified technology is introduced.

606

607 *Data Analysis:*

608 You should provide raw data sets as well as a summary table for all results in your
609 submission. Please note that the summary tables should be presented separately for each
610 test strip lot and glucose level tested. Table 4 below provides a sample format.

611

Table 4. Recommended Summary Table Format:

612

Lot 1/Glucose Concentration (60 mg/dL)

613

Potential Interferent: Acetaminophen

614

Mean Glucose Value (YSI)	Interference Level	Mean Glucose (Meter)	Bias (mg/dL)	% Bias	Confidence Interval
60 mg/dL	20 µg/mL				
	100 µg/mL				
	200 µg/mL				


615

616 We recommend you also present data graphically for each individual test strip lot.
617 Graphs should describe the percent bias for all data points included in the study at
618 therapeutic, toxic and any intermediate levels. The graph should include the mean
619 glucose measurement obtained by the meter as well as the confidence intervals around the
620 bias. A sample graph is shown below:

621

622

Figure 1. Sample Format for Interference Graph



623

624

625

626

627

628

In your 510(k) you should include a detailed description of the study design, a list of all data collected in this study, the summary tables and graphs indicated above and a description of the conclusions drawn from the study.

629

2. Hematocrit

630

Study Design:

631

632

633

634

635

636

637

638

639

640

641

642

643

644

You should evaluate the effect of hematocrit on the performance of your system to assess whether the device can be used safely in the intended use population across your claimed hematocrit range. The observed hematocrits may be very broad in the intended use population for this type of device; the majority of intended users may reasonably be expected to have hematocrit values between 20 and 60% hematocrit. Therefore, we recommend 20-60% hematocrit as the claimed range for this type of device. If your device is subject to significant interference from hematocrit within that range, you should include limitation statements in your labeling cautioning against use when certain physiological conditions are present or suspected (e.g., anemia, etc.). Because lay users generally have no way to adequately determine their hematocrit status, devices that cannot adequately measure glucose across the range of 30-55% hematocrit (which includes the greatest proportion of users) cannot be safely used to monitor blood glucose and may not be determined to be substantially equivalent.

645

646

647

648

649

650

651

652

Because a reasonably sized method comparison study still may not include the full range of hematocrit values expected in the intended use population, you should perform a separate study to determine how much analytical error may be contributed by this condition. You should evaluate hematocrit interference by measuring samples containing various glucose concentrations in reconstituted blood. The samples should be prepared to contain designated levels of hematocrit that span the claimed hematocrit range for the device. The blood sample may be adjusted by spiking or allowing it to glycolyze to obtain the desired glucose concentration. Specific percentages of hematocrit may be

*Contains Nonbinding Recommendations
Draft - Not for Implementation*

653 achieved for each sample by manipulating the plasma to packed cell ratio following
654 centrifugation. Hematocrit levels tested should span the claimed range in 5% intervals.
655 For example, if your claimed hematocrit range is from 20-60%, you should test samples
656 at 20, 25, 30, 35, 40, 45, 50, 55, and 60 % hematocrit. The samples should also span the
657 claimed measuring range for blood glucose. Samples should include 5 different blood
658 glucose concentrations evenly spread and targeted to the following ranges: 30 – 50, 51 –
659 110, 111 – 150, 151 – 250, and 251 – 400 mg/dL.

660

661 Each sample should be tested on the reference method in multiple replicates (a minimum
662 of 4). An average of reference measurements, for example, may give greater confidence
663 in the true glucose concentration of the sample.

664

665 A minimum of 3 test strip lots should be used to evaluate interference from hematocrit.
666 Each test sample should be tested on your new SMBG device in replicates of 30 (10
667 replicates per lot of test strips, for a total of 30 replicates per sample). Each replicate
668 should be compared to the average reference value for the sample and a bias and % bias
669 calculated. The percent bias for each replicate should be used to produce an average
670 percent bias for the sample (with 95% confidence intervals).

671

672 Because hematocrit interference is only one of the variables that will contribute to the
673 overall analytical error of the system, it is important that it represent only a portion of the
674 allowable error for the system. For this reason, bias observed in this study should be less
675 than 8% on average, and no individual value should be greater than 15% of the reference
676 method.

677

678 *Data Analysis:*

679 You should provide raw data sets as well as a summary of the hematocrit interference
680 study (see recommended format below). Please note that the summary tables should be
681 presented separately for each test strip lot and glucose level tested.

682

683 **Table 5: Sample Format for Hematocrit Results:**


684 *Lot 1, Glucose Level 1 (30-50 mg/dL)*

Mean Glucose Value (YSI)	Hct (%)	Mean Glucose Value (Meter)	Bias (mg/dL)	% Bias	# of Observations > +/- 15% Bias

685

686 You should also present the data graphically for each individual test strip lot. Graphs
687 should include percent bias for all data points included in the study. The graph should
688 include confidence intervals around the percent bias

Figure 2: Sample Format for Hematocrit Interference Graph



689
690
691
692
693
694

You should submit a detailed description of the study design, a list of all data collected in this study, the summary tables and graphs indicated above, and a summary of the conclusions drawn from the study.

695 ***E. Flex Studies***

696 There are typically fewer controls in place in OTC settings to mitigate risk. In addition,
697 the users are often untrained and may not know how to identify or address an incorrect
698 result. It is therefore assumed that the OTC devices are designed so the risk of an
699 erroneous result should be far less than with laboratory-based tests. You should therefore
700 demonstrate that your SMBG device design is robust (e.g., insensitive to environmental
701 and usage variation) and that all known sources of error are effectively controlled. In
702 general, flex studies should be used to demonstrate robust design while risk management
703 should be used to demonstrate identification and effective control of error sources,
704 although the two are not mutually exclusive.

705
706 Most risk control measures should be fail-safe measures or failure alert mechanisms.
707 Examples of fail-safe mechanisms are lock-out functions to ensure that a test system does
708 not provide a result when test conditions are inappropriate, such when there is a
709 component malfunction or operator error. Other examples are measures within the system
710 to prevent operator error, such as guides or channels that prevent improper strip
711 placement. We recommend that test system design incorporate fail-safe mechanisms
712 whenever it is technically practicable. If fail-safe mechanisms are not technically
713 practicable for some risks, failure alert mechanisms should be used. Failure alert
714 mechanisms notify the operator of any test system malfunction or problem. They may
715 include measures such as internal procedural controls or electronic controls. Devices with
716 such mechanisms allow the operator to correct the error, or put the operator on notice that
717 the results will be unreliable due to the error. For example, in cases where the result

Contains Nonbinding Recommendations
Draft - Not for Implementation

718 exceeds the reportable range (e.g., extremely high or low glucose result) and the result is
719 a critical value, the device should give a message such as "out of range high" or "out of
720 range low."

721
722 Flex studies, or studies that stress the operational limits of a test system should be used to
723 validate the insensitivity of the test system to performance variation under stress
724 conditions. Where appropriate, flex studies should also be used to verify and/or validate
725 the effectiveness of control measures at operational limits. Flex studies are particularly
726 important for OTC SMBG devices as these devices are intended for use by lay users and
727 undergo a variety of environmental and user-associated conditions that could affect
728 system performance.

729
730 In order to identify all relevant flex studies for your SMBG device, we recommend that
731 you conduct a systematic and comprehensive risk analysis that identifies all potential
732 sources of error, including test system failures and operator errors, and identifies which of
733 these errors can lead to a risk of a hazardous situation. You should then identify control
734 measures, including fail-safe and failure alert mechanisms that will reduce risks for these
735 sources of error. When the control measures have been implemented, you should (1)
736 verify that each control measure has been properly implemented, and (2) verify and/or
737 validate the effectiveness of each control measure. When appropriate, flex studies should
738 be used to verify and/or validate the effectiveness of these control measures.

739
740 Below we have identified several flex studies that we believe are important for you to
741 perform in order to demonstrate adequate performance of OTC SMBG systems. At the
742 same time, we continue to encourage you to perform risk analyses to determine whether
743 your device includes any unique or new features that should be validated through flex
744 studies.

745
746 If your SMBG device does not perform adequately in flex studies, we recommend you
747 either provide a justification, determined by means of thorough risk analysis, as to why
748 adequate performance under that flex study is not required for safe effective use of the
749 device or indicate an additional validated control mechanism implemented to assure safe
750 and effective use of the device. FDA will review such justifications to determine whether
751 the proposed mitigation strategies are adequate to protect patients.

752
753 In the case of the following flex studies, it is acceptable for you to provide documentation
754 indicating that flex studies have been conducted in accordance with a recognized industry
755 standard. We recommend you include the type of testing performed, the reference
756 standard followed, the acceptance criteria, and whether the SMBG device passed testing
757 requirements.

758
759 The flex studies we recommend performing in this manner are:

- 760 • Mechanical Vibration Testing
- 761 • Shock Testing

*Contains Nonbinding Recommendations
Draft - Not for Implementation*

- 763 • Electromagnetic compatibility (EMC) Testing
764 • Electrostatic Discharge/Electromagnetic Interference Testing

765

766 Unless otherwise indicated, we recommend that you clearly identify all flex studies
767 performed on your device in your premarket submission. A detailed description of the
768 following attributes should be included:

769

- 770 • Study goal
771 • Study protocol and methods
772 • Methods used to apply samples to test strips
773 • Description of sample type and any anticoagulants used
774 • Study results
775 • Description of conclusions made from the study

776

777 We have also identified additional flex studies that we believe are important for
778 manufacturers to perform in order to demonstrate adequate system performance in
779 intended use settings. A list of these recommended flex studies as well as recommended
780 study designs are included below.

781

782 ***1. Test Strip Stability Testing***

783 You should perform a study to assess test strip performance throughout its claimed shelf
784 life. We request that you submit only the study protocol, the acceptance criteria for the
785 test strip stability study, and the conclusions of the study.

786

787 You should evaluate precision and accuracy of test strips at various time points
788 throughout their stated shelf life. You should indicate the time points that are assessed in
789 this stability protocol (e.g. 1 month, 3 months, 2 years); a combination of real-time and
790 accelerated aging studies are acceptable. You should perform both precision and
791 accuracy evaluations at each identified time point as described below. Through these
792 evaluations, you should demonstrate that the CV calculated in this study is within the
793 labeled performance of the SMBG device.

794

795 *Precision Evaluation:*

796 Precision with Control Materials

797 This study should be completed over 5 days and use glucose controls. At least two
798 SMBG devices should be included in this study and at least 10 measurements should
799 be taken per control level per meter.

800

801 Precision with Whole Blood Samples

802 This study should be completed over 10 days using whole blood samples spanning the
803 SMBG device's stated measuring range. Samples may be altered by spiking with
804 glucose or allowing the samples to glycolyze in order to evaluate the extreme end of
805 the system's measuring range. At least two SMBG devices should be included in this
806 study and at least 10 measurements should be taken per glucose level, per meter.

807

808 *Accuracy Evaluation:*

809 The study should be performed using patient whole blood samples that span the SMBG
810 device's stated measuring range. It is acceptable for samples to be spiked with a known
811 concentration of glucose, or allowed to glycolyze to achieve the desired concentration in
812 order to evaluate the extreme ends of the system's measuring range. Glucose
813 concentrations should be measured on the SMBG meter and compared to values obtained
814 with the reference method.

815

816 **2. Temperature and Humidity Effects on SMBG Device**

817 We believe the following recommendation for conducting temperature and humidity
818 effects studies most closely represents actual use conditions experienced by users of OTC
819 SMBG devices.

820

821 We recommend the simultaneous evaluation of temperature and humidity effects on
822 blood glucose meters and blood glucose test strips under "Open Vial" (i.e. to mimic use
823 of test strips after an individual user has opened a test strip vial) and "Extended Open
824 Vial" (i.e. to mimic use of test strips from vials that have been left completely open for
825 the duration of the claimed test strip vial shelf-life) conditions. Separate testing of test
826 strip and meter shipping and storage conditions are not necessary if, for these temperature
827 and humidity studies, only packaged blood glucose meters and blood glucose test strips
828 that have undergone appropriate storage conditions and the longest possible shipping
829 duration (both as specified by the manufacturer) are used. In addition, tested temperature
830 and humidity ranges should not only cover the claims specified in the device labeling, but
831 test conditions should also stress the SMBG device and include ranges outside of labeling
832 claims. We recommended that you test the effects of fluctuating temperate and humidity
833 on blood glucose meters and blood glucose test strip performance, as well as effects of
834 heat and humidity changes across the open vial shelf life. We recommend you use
835 multiple meters and test strip vials in these studies.

836

837 We recommend that you present results for temperature and humidity studies as the mean
838 values of measurements per meter. You should also include corresponding standard
839 deviations (SD) and coefficients of variation, as well as the grand mean, pooled variance,
840 pooled standard deviation (with 95% confidence intervals) and pooled CV. You should
841 describe your statistical methods. For statistical analysis, ANOVA is the preferred
842 method for calculating intermediate precision. You should also include a summary of any
843 identified outliers that were excluded from statistical analysis, the method of outlier
844 identification and the results of outlier investigations.

845

846 We encourage manufacturers to also consider ways in which temperature and/or humidity
847 detectors might be incorporated into test strip containers to alert users when strips have
848 not been handled correctly or stored according to recommended and validated conditions.

849

850 **3. Altitude Effects**

851 You should evaluate the effect of altitude on performance for your SMBG devices by
852 comparing results from whole blood samples with the candidate device to the reference
853 method. These studies should include a pressure change. Studies based on oxygen
854 tension instead of pressure change are not adequate, because oxygen tension is only one
855 component that changes with altitude. Altitude pressure changes can be accomplished by
856 physically increasing altitude (e.g., in an airplane, on a mountain), or by simulating
857 increasing altitudes and atmospheric conditions in a pressurized chamber. Results should
858 support the altitude labeling claim for your device. You should provide your definition
859 for terms, such as “sea level”. The definition of sea level should not extend past 500 feet.
860 You should test your SMBG device at a minimum of 10,000 feet above sea level.

861

862 **4. Short Sample Detection**

863 Blood glucose measurement from short samples (samples of reduced volume) can lead to
864 inaccurate results. To avoid the risk of inaccurate results, SMBG devices should be able
865 to detect that a short blood sample has been applied to the test strip and should not
866 provide a result to the user. Short sample detection systems should not rely on visual
867 verification by the user.

868

869 The volume required to classify a test sample as a short sample is dependent upon the
870 SMBG device. In your short sample detection studies you should include blood samples
871 with known glucose concentrations in the following three ranges: 50-65 mg/dL, 100-120
872 mg/dL, and 200-250 mg/dL. You should test blood samples with your candidate SMBG
873 device at each of the glucose concentrations listed above. Blood samples with serially
874 reduced volumes should be measured on the device until an error is either generated by
875 the device or the test result falls outside of the device’s stated performance range. Results
876 obtained from the candidate device should be compared to the reference method. In your
877 submission you should describe the results from both the candidate device and the
878 reference method, as well as the sample volume tested for each of the tested glucose
879 concentration ranges.

880

881 **5. Sample Perturbation Study**

882 Sample perturbation occurs when a user has applied an appropriate volume of blood to
883 the test strip for glucose measurement but an event such as wicking of blood away from
884 the test strip, flicking of the test strip or flicking of the meter occurs during the start of
885 measurement and alters the volume of the initial sample application. Sample perturbation
886 often leads to a short sample.

887

888 You should adequately demonstrate how your SMBG handles sample perturbation,
889 through a sample perturbation study. In such a study, once a sample has been applied to
890 the test strip and the SMBG device has begun to read the sample, the test strip should be
891 perturbed. The sample perturbation study should incorporate blood samples with known
892 glucose concentrations in the following three ranges: 50-65 mg/dL, 100-120 mg/dL, and
893 200-250 mg/dL. In your 510(k) submission you should describe your protocol, including

894 your specific method of perturbing the test sample, as well as meter results compared to
895 the reference method.

896

897 **6. Intermittent Sampling**

898 Intermittent sampling occurs when a short sample is applied to a test strip, a glucose
899 measurement begins, and the user adds more sample to the test strip before the glucose
900 measurement is complete.

901

902 You should adequately demonstrate how your SMBG handles intermittent sampling by
903 conducting a study. The intermittent sampling study should incorporate blood samples
904 with known glucose concentrations in the following three ranges: 50-65, 100-120, and
905 200-250 mg/dL. You should perform intermittent sampling studies that are representative
906 of actual events. For instance approximately one half of the sample should be applied to
907 the test strip prior to the start of sample measurement, then the other half of the sample
908 should be applied to the strip once the sample starts reading. You should describe how
909 the device responds to this scenario, including whether a result is reported, whether this
910 result is accurate (relative to the reference method) and when an error code is reported.

911

912 **7. Testing with Used Test Strips**

913 We recommend that SMBG devices be designed to automatically recognize the insertion
914 of used test strips. Insertion of used test strips into a blood glucose meter should not
915 provide glucose measurement results to the user. If an automatic used test strip
916 recognition function has been incorporated into your SMBG device, you should perform a
917 flex study to demonstrate the functionality of this recognition system. If an automatic
918 used test strip recognition function has not been incorporate into the design of the blood
919 glucose meter, you should submit flex study results demonstrating that the insertion of
920 used strips for glucose testing generates an appropriate error code to the user. In your
921 submission you should provide the study protocol, acceptance criteria and results.

922

923 ***F. Calibration and External Control Materials***

924 The use of external control solutions allows consumers to periodically check the accuracy
925 of the SMBG device and test strip. In order to further promote the use of external control
926 solutions by the user, you should include at least two levels of control materials to the
927 customer with each test strip vial. We recommend you follow FDA's "Guidance for
928 Industry and FDA Staff - Assayed and Unassayed Quality Control Material"
929 [[http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocument
930 s/ucm079179.htm](http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocument/s/ucm079179.htm)] and submit the recommended information to support clearance of your
931 assayed glucose quality control material.

932

933 Control solutions provided should not be labeled in a descriptive manner such as "low",
934 "normal," or "high" since that may be misleading to the user. Users may confuse a label
935 that says "normal" as meaning that that is a clinically normal value even when the control
936 concentration is not within the normal range that is recommended by an individual user's

937 physician. Control solutions should be labeled non-descriptively (e.g., numerically - 1, 2,
938 3).
939

940 For a description of more points to consider regarding calibration and quality control
941 materials, please reference the guidance document “In Vitro Diagnostic Devices:
942 Guidance for the Preparation of 510(k) Submissions – Appendix K – Points to Consider
943 for Review of Calibration and Quality Control Labeling for In Vitro Diagnostic Devices”
944 ([http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocument](http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm094635.htm)
945 [s/ucm094635.htm](http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm094635.htm)).
946

947 You should describe how the candidate system recognizes and distinguishes calibration or
948 control materials from patient specimens as well as explain how the system compensates
949 for differences between strip lots or strip types.
950

951 **VII. Test Strip Lot Release Criteria**

952
953 Your test strip lot release criteria should be sufficient to ensure consistent performance of
954 your SMBG test strips. You should provide a description of the lot release criteria and a
955 summary of the sampling scheme in your premarket notification.
956

957 We recommend that you select a sampling scheme appropriate for the operation of your
958 device and test each outgoing test strip lot or batch using the precision and accuracy
959 evaluations described below. Your release criteria should be designed to ensure that all
960 released lots conform to the labeled SMBG device performance *in the hands of the intended*
961 *user*. Therefore, these criteria should be more stringent than the criteria used to evaluate total
962 error in the user studies. Estimates of the device’s imprecision and average bias may be used
963 to determine appropriate criteria. For example, if the device has an average CV of 3% and an
964 average bias of 5%, these may be considered in determining the appropriate lot release
965 criteria.
966

967 *Precision Evaluation:*

968 Precision using Control Materials

969 This study should be completed over 5 days and use glucose controls. At least two
970 SMBG devices should be included in this study and at least 10 measurements should
971 be taken per control level per meter.
972

973 Precision using Whole Blood Samples

974 This study should be completed over 10 days using whole blood samples spanning
975 the SMBG device’s stated measuring range. Spiking samples with glucose, or
976 including samples in which glucose was allowed to glycolyze is acceptable in order
977 to evaluate the extreme end of the system’s measuring range. At least two SMBG
978 devices should be included in this study and at least 10 measurements should be
979 taken per glucose level, per meter.
980

981 *Accuracy Evaluation:*

982 The accuracy evaluation should be performed using patient whole blood samples that span
983 the SMBG device's stated measuring range. It is acceptable for samples to be spiked with a
984 known concentration of glucose, or to include samples in which the glucose was allowed to
985 glycolyze in order to evaluate the extreme ends of the system's measuring range. Glucose
986 concentrations should be measured on the SMBG meter and compared to the reference
987 method.

988

989 *Third Party Test Strips:*

990 Third party test strips refer to test strips manufactured and distributed by a company other
991 than the company that manufactures and distributes the glucose meter. Third party strip
992 manufacturers should ensure that they are aware of any design changes to the meter, because
993 such changes could affect compatibility of the strip with the meter. We strongly recommend
994 that agreements between the third party strip manufacturer and the meter manufacturer are in
995 place to ensure that the third party strip manufacturer is made aware of any design changes to
996 the meter. In cases where this is not possible, the third-party strip manufacturers should
997 sufficiently address, in their submission, how they will mitigate the risk of incorrect results
998 due to meter design changes.

999

1000 **VIII. Software**

1001

1002 For software descriptions of SMBG devices, their components, and accessories, we
1003 recommend that you follow **Guidance for the Content of Premarket Submissions for**
1004 **Software Contained in Medical Devices**,
1005 [http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocument](http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm089543.htm)
1006 [s/ucm089543.htm](http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm089543.htm). Generally, FDA considers glucose meters to be a moderate level of
1007 concern because glucose results will be the basis for treatment, including determination of
1008 insulin dosage by the patient or health care provider. Incorrect glucose results or failure of
1009 the software to detect an error could result in improper diabetes management. (Also see
1010 Section VI, above regarding software descriptions in your 510(k)).

1011

1012 **IX. Labeling**

1013

1014 The labeling of a SMBG includes a user manual, package inserts for both test strips and
1015 controls, and box and container labels for the meter, test strips, and control materials. The
1016 package inserts for test strips and controls, and the user manual should be simple, concise,
1017 and easy to understand. Graphics such as line drawings, illustrations, icons, photographs,
1018 tables, and graphs are very useful tools. Manufacturers should ensure that the same terms are
1019 used consistently throughout the labeling to identify the device and its parts, avoiding
1020 synonyms or alternate phrases. Symbols should not be used in the labeling of OTC devices.
1021 We recommend that you refer to the following documents for information on important
1022 principles for developing clear and complete home use IVD labeling:

1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066

- **Guidance on Medical Device Patient Labeling; Final Guidance for Industry and FDA (2001),**
<http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm070782.htm>.
- **Labeling of Home-Use In Vitro Testing Products; Approved Guideline, CLSI GP-14 (1996).**
- Device Advice website titled **Labeling Requirements - In Vitro Diagnostic Devices** [<http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/DeviceLabeling/InVitroDiagnosticDeviceLabelingRequirements/default.htm>]

Technical information, required by 21 CFR 809.10(b), should be described so that lay users can understand the information or locate it if necessary. Detailed technical information (e.g., chemical details of test principle or statistical analyses of data) may be presented in a separate section followed by clarifying statements appropriate for lay users.

The premarket notification must include labeling in sufficient detail to satisfy the requirements of 21 CFR 807.87(e). Final labeling must also satisfy the requirements of 21 CFR 809.10.

The following items are intended to further assist sponsors in complying with the requirements of 21 CFR 809.10 for test strip and meter labeling.

1. The device container and package insert must contain the proprietary and common names of the device. 21 CFR 809.10(a)(1) and 21 CFR 809.10(b)(1). The various test system components should have the same name (ABC blood glucose test system, ABC blood glucose meter, ABC blood glucose test strips, etc.) to aid in identification of system components.
2. You must include on the label and labeling the intended use of the product. 21 CFR 809.10(a)(2) and 21 CFR 809.10(b)(2). The intended use for OTC SMBG devices should be similar to the example below:

The XYZ Blood Glucose Monitoring System is intended for use in the quantitative measurement of glucose in capillary whole blood from the finger. It is intended for use by people with diabetes mellitus at home as an aid in monitoring the effectiveness of a diabetes control program. The XYZ Blood Glucose Monitoring System is intended to be used by a single person and should not be shared.
3. You must include warnings appropriate to the hazard presented by the product. (21 CFR 809.10(b)(5). You should include the following warning *prominently* on the outer box labeling and package insert.

This device is not intended for use in healthcare or assisted-use settings such as hospitals, physician’s offices, or long-term care facilities because it has not been

1067 **determined to be safe and effective for use in these settings, including for routine**
1068 **assisted testing or as part of glycemic control procedures.**

1069
1070 **Use of this device on multiple patients may lead to transmission of Human**
1071 **Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Hepatitis B Virus (HBV),**
1072 **or other bloodborne pathogens.**

- 1073
- 1074 4. Labeling must include the chemical, physical, physiological, or biological principles of
1075 the procedure (21 CFR 809.10(b)(4)). The discussion of these principles should include
1076 identification of the enzyme and description of the reaction. Labeling should specify
1077 whether results are determined in terms of whole blood or plasma equivalents. SMBG
1078 devices intended for use in the U.S. should report results in terms of plasma equivalents.
1079
- 1080 5. The label must include a means by which the user may be assured that reagents meet
1081 appropriate standards of identity, strength, quality and purity at the time of use.
1082 (809.10(a)(6)).
1083
- 1084 6. The labeling must provide instructions for specimen collection and preparation. (21 CFR
1085 809.10(b)(7)). Instructions should include a statement to users on the importance of
1086 thoroughly washing and drying the skin before taking a sample, because contaminants on
1087 the skin may affect results. See also instructions for cleaning and disinfection , below.
1088
- 1089 7. The labeling must provide a step-by-step outline of recommended procedures (21 CFR
1090 809.10(b)(8)), and operating instructions for the instrument (21 CFR 809.10(b)(6)(v)).
1091 Numbering, rather than bullets should be used for clarity when appropriate (e.g.
1092 procedural steps, etc.). You should include this information in the User Manual.
1093
- 1094 8. Labeling must include a statement of limitations of the procedure including known
1095 extrinsic factors or interfering substances affecting results (21 CFR 809.10(b)(10)). You
1096 should include testing conditions that may cause clinically significant errors (due to bias
1097 or imprecision) with your device (e.g., specific drugs, oxygen therapy, high altitude). You
1098 should indicate the most extreme conditions (e.g., the highest altitude) at which device
1099 should be used based on the results of performance testing.
1100
- 1101 9. You should clearly indicate to users what display they will expect to see when their
1102 measured glucose is lower or higher than the measuring range of the meter. For example,
1103 meter XYZ has a measuring range that goes down to 50 mg/dL. All glucose values
1104 measured below 50 mg/dL will provide the following error code: “Less than 50”. Meter
1105 XYZ’s labeling would include a statement explaining this error code: “When your
1106 glucose value is less than 50 mg/dL you will see the following error code ‘Less than 50’”.
1107
- 1108 10. Labeling must describe details of calibration and of quality control procedures (21 CFR
1109 809.10(b)(8)(v) and 21 CFR 809.10(b)(8)(vi)). This is to help ensure optimal
1110 performance of the system. This section should include recommendations for how and
1111 when to perform quality control checks and instructions for what to do if the control

Contains Nonbinding Recommendations
Draft - Not for Implementation

1112 material values are not within the manufacturer’s allowable range. As part of the quality
1113 control information in your labeling, we recommend sponsors advise users that they
1114 should periodically review their technique and compare a result obtained with their meter
1115 to a result obtained using a laboratory method or a well-maintained and monitored system
1116 used by their healthcare provider.

1117

1118 11. Labeling must include expected values (21 CFR 809.10(b)(11)). FDA recommends that
1119 the expected values in the package insert should be those for non-diabetics. FDA does
1120 not recommend including additional ranges adjusted for diabetics because such ranges are
1121 individualized and determined by the clinician. The expected values should be cited from
1122 in-house studies or up-to-date reference sources.

1123

1124 12. Labeling must include specific performance characteristics (21 CFR 809.10(b)(12)).
1125 Sponsors should briefly describe all studies and summarize results in the package inserts.
1126 FDA recommends that this include performance data summaries from in-house and user
1127 studies. For presentation of accuracy in particular, see the charts below for an example.
1128 Performance should be presented separately for each anatomical site and matrix.

1129

1130 Accuracy information:

1131 So that home users have the ability to choose the SMBG device that is right for them, it is
1132 important to clearly describe the performance of the device in a way that is easy for them
1133 to understand. It is also important for this information to be located in a prominent place
1134 in product labeling so that lay users can understand the performance of an individual
1135 SMBG device both prior to purchase and also when they are learning to use the device
1136 they have purchased. Therefore, both the outer box labeling and the package insert
1137 should have easily understood depictions of the clinical study results.

1138

1139 In the package insert for the test strips and the user manual for the SMBG device,
1140 accuracy information should be prominently and logically placed within the label. We
1141 recommend that this information be included in the section where the manual describes
1142 how a user will obtain a result. In the test strip insert, this section should be large and
1143 centrally placed so that users understand the performance of the system using these test
1144 strips. We recommend the following types of presentations to represent the results of
1145 your accuracy studies in the user manual and test strip inserts.

1146

Suggested Representation of Accuracy for Lay Users - Example


Your ABC Meter result may vary slightly from your actual blood glucose value. This may be due to slight differences in technique and the natural variation in the test technology.

The chart below shows the results of a study where 350 typical users used the ABC meter to test their blood glucose level. For example, in this study, the ABC meter gave results within 15% of their true blood glucose level 340 out of 350 times.

Difference range between the true blood glucose level and the ABC meter result.	Within 5 %	Within 10 %	Within 15 %	Within 20%
The percent (and number) of meter results that match true blood glucose level within x%	57% (200/350)	94% (330/350)	97% (340/350)	100% (350/350)

1147
1148
1149
1150
1151
1152
1153
1154

Accuracy information should also be included on the SMBG device and test strip outer box labeling and test strip vials as well as in the package inserts and user manual. We recommend that this outer box label accuracy information refer readers to the package insert and graphically represent the user study data. An example of this type of presentation is shown below. Numbers represent the number of meter results that were within the level of accuracy shown, relative to the laboratory device.



1155
1156

Accuracy key	Percentages listed are meter values as compared to laboratory values
Accurate	+/-15%
More Accurate	+/-10%
Most Accurate	+/-5%

1157
1158

*Contains Nonbinding Recommendations
Draft - Not for Implementation*

- 1159 13. You must describe the principles of operation for the instrument as well as service and
1160 maintenance information (21 CFR 809.10(b)(6)). Labeling should include a list or
1161 summary of error messages, descriptions of what those error messages mean, and
1162 appropriate troubleshooting procedures for those error messages.
1163
- 1164 14. You should provide a working U.S. toll free telephone number for user assistance in the
1165 manual and package insert, and include hours of operation. If user assistance is not
1166 provided 24 hours/7 days a week/365 days a year, sponsors should provide instructions
1167 for what measures the user should take when user assistance is not available.
1168
- 1169 15. The label and labeling must include statements of warning or precautions as appropriate
1170 to the hazard presented by the product (21 CFR 809.10(a)(4), (b)(5)(ii)). We recommend
1171 that you include instructions to lay users to contact their healthcare provider, if they
1172 obtain results that are not consistent with the way they feel, and to not change their
1173 medication regimen without approval from a healthcare provider.
1174 You should clearly and prominently state the important warnings for this device in the
1175 front of the label, in a section containing **Important Safety Instructions**. Important
1176 warnings and safety information should be included on all test system instructions (User
1177 manual, test strip labeling, etc.):

1178
1179 You should stress the risk of disease transmission when using SMBGs and reference any
1180 relevant public health notifications, standard practice guidelines, or other resources
1181 available to users. At a minimum, the following warnings should be included:

- 1182
- 1183 • The meter and lancing device are for single patient use. Do not share them with
1184 anyone including other family members! Do not use on multiple patients!
 - 1185 • All parts of the kit are considered biohazardous and can potentially transmit
1186 infectious diseases, even after you have performed cleaning and disinfection.
- 1187

1188 You should include these references:

1189
1190 *“FDA Public Health Notification: Use of Fingertick Devices on More than One*
1191 *Person Poses Risk for Transmitting Bloodborne Pathogens: Initial Communication”*
1192 *(2010)*

1193 <http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm224025.htm>

1194
1195 CDC website on *“Infection Prevention during Blood Glucose Monitoring and Insulin*
1196 *Administration”*, <http://www.cdc.gov/injectionsafety/blood-glucose-monitoring.html>

1197
1198 In the section(s) describing **how to obtain a blood sample**, you should re-iterate the risk
1199 of bloodborne pathogen transmission. You should stress that a lancing device is intended
1200 only for a single user and should not be shared. You should stress that users should clean
1201 hands thoroughly with soap and water after handling the meter, lancing device, or test
1202 strips.
1203

Contains Nonbinding Recommendations
Draft - Not for Implementation

1204 The user manual should contain detailed instructions for how and when users should
1205 perform **cleaning and disinfection procedures** for the meter and/or lancing devices,
1206 based on the validation studies performed. Specifically the instructions should include
1207 the following:

- 1208
- 1209 • An explanation of why the cleaning and disinfection should be performed in
1210 language that is appropriate for the intended user audience. You should explain
1211 the difference between “cleaning” and “disinfection.”
- 1212 • The recommended frequency. For example, the meter should be cleaned and
1213 disinfected at a minimum of once per week. An explanation should be provided
1214 for how this number relates to the number of validated cycles over the life of the
1215 device. The use life of the device should be clearly stated.
- 1216 • A list of the materials needed for cleaning and disinfection should be provided.
1217 Instructions on how these products can be purchased or prepared need to be
1218 clearly outlined.
- 1219 • A detailed procedure describing what parts of the device should be cleaned and
1220 disinfected, the amount of time the cleaner or disinfectant needs to remain on the
1221 meter or lancing device (contact time), etc. You should include
1222 graphics/photographs to assist the user.
- 1223 • A statement that users should clean hands thoroughly with soap and water after
1224 handling the meter, lancing device, or test strips.
- 1225 • A contact telephone number for technical assistance or questions should be
1226 prominently listed in the cleaning and disinfection section along with a list of
1227 signs of external deterioration and deteriorating performance that the user should
1228 look for.
- 1229

- 1230 16. If studies have not been presented supporting the use of alternative site testing (AST) for
1231 a SMBG device, you should include a prominent warning in the labeling against use of
1232 the device for AST. Sampling from anatomical sites other than the fingertip, i.e.,
1233 forearm, upper arm, thigh, calf, palm, may be indicated for some SMBG devices.

1234

1235 Some users may prefer obtaining blood from alternative sampling sites because of less
1236 pain or greater choice in puncture sites. However, studies have shown that during times
1237 of rapidly changing glucose (i.e., after meals, medication, or exercise), the glucose level
1238 in blood from the alternative site may be significantly different from the glucose level
1239 from the finger. Additionally, glucose levels may not rise as high or fall as low as levels
1240 in the fingertip. This can result in a delay, or a failure to detect, hypoglycemia when
1241 glucose is measured in alternative sites during non-fasting times.

1242

1243 When alternative sampling sites have been validated, and are indicated, you should clarify
1244 that results from these sites may lag behind finger stick during periods of glucose change,
1245 or reduced peripheral circulation (e.g., shock).

Contains Nonbinding Recommendations
Draft - Not for Implementation

1247 If the AST studies conducted do not include any challenges evaluating rapid increases or
1248 decreases of glucose levels, you should include the following limitations in your package
1249 insert:

1250

1251 • Alternative site results may be different from fingertip results when glucose levels
1252 are changing rapidly (e.g., after a meal, after taking insulin, or during or after
1253 exercise).

1254 • Do not rely on test results at an alternative sampling site, but use samples taken
1255 from the fingertip, if any of the following applies:

1256

1257

1258

1259

1260

1261

1262

1263

1264

1265

1266

1267

1268

- you think your blood sugar is low.
 - you are not aware of symptoms when you become hypoglycemic.
 - the site results do not agree with the way you feel.
 - after a meal.
 - after exercise.
 - during illness.
 - during times of stress.
- Do not use results from alternative site samples to calibrate continuous glucose monitoring systems (CGMS), or for insulin dose calculations.

1269

1270

Appendix 1. Potential sources of error to consider for SMBG Devices

1271

1272

1273

1274

1275

1276

1277

1278

The following table lists potential sources of error associated with the design, production, and use of SMBG devices. We do not intend for this to be a complete list. You should consider all sources of error based on your knowledge of your specific device. Documents such as CLSI EP-18A and ISO 14971 also provide lists of preanalytical, analytical, and post-analytical errors to consider.

Category	Source of error or failure
Operator	<p>Failure to follow procedure correctly, for example:</p> <ul style="list-style-type: none"> • Sample contamination • Incorrect specimen collection (e.g., poor lancing technique and incorrect volume) • Application of an insufficient amount of blood to the strip or incorrect application of blood to strip • Use of a sample from an alternative site at inappropriate times or from a site not validated by the manufacturer • Application of the specimen to the strip more than once (for example, if the user believes not enough specimen was added the first time) • Incorrect insertion of strip into meter • Inaccurate timing • Use of contaminated, outdated, or damaged strips or reagents, including calibrators or quality control materials • Failure to understand or respond to meter output. • Errors in meter maintenance or cleaning • Errors in calibration or failure to calibrate or otherwise adjust the meter or check performance with quality control materials, as directed by labeling • Incorrect saving or use of stored data • Improper storage or handling of the meter, calibrators, quality control materials or test strips, or maintenance of the meter • Inadvertent changes of parameters (such as units of measurement) • Failure to contact physician when necessary (OTC) • Incorrect incorporation of results into overall treatment plan (professional use) • Use of strips not validated for use on the monitor
Reagent	<ul style="list-style-type: none"> • Expired strips or reagents

*Contains Nonbinding Recommendations
Draft - Not for Implementation*

	<ul style="list-style-type: none"> • Damaged or contaminated strip • Failure of strips, calibrators, or quality control materials to perform adequately • Incorrect manufacturing; product fails to conform with specifications • Incorrect dimensions of reagent strip • Interference with chemical reaction on strip (e.g., reducing substances) • Inadequate design of container for strips or other reagents; failure to prevent deterioration; failure of desiccant used to keep strips dry
Environmental	<ul style="list-style-type: none"> • DEVICE EFFECTS <ul style="list-style-type: none"> • Temperature • Humidity • Altitude; hyperbaric conditions • Electromagnetic radiation • Visible light; sunlight • HUMAN FACTORS <ul style="list-style-type: none"> • Lighting, glare off meter surfaces • Distractions, visual and auditory • Stressful conditions • Limited manual dexterity
Software	<ul style="list-style-type: none"> • Confusing or obscure user prompts and feedback • Incorrect mathematical algorithm • Undetected or unrecognized signal errors • Timing failure • Incorrect storage of test results in memory, including matching result with correct patient or time of test • Other software failures
Hardware	<ul style="list-style-type: none"> • Electronic failure • Physical trauma or vibration • Damage to the device from incorrect strip dimensional tolerances (third party manufacturer) • Electrostatic discharge • Electromagnetic/radiofrequency interference • Battery reliability, lifetime, and replacement • Component(s) failure • Incorrectly manufactured

*Contains Nonbinding Recommendations
Draft - Not for Implementation*

System	<ul style="list-style-type: none">• Physical trauma or vibration• Incorrect calibration/adjustment (between lots of strips)• Calibration failure, interference, instability or use beyond the recommended period of stability.• Labeling not geared to intended user.• Meter or operation complexity not geared to intended user• Inadequate training
Clinical	<ul style="list-style-type: none">• Interference from endogenous substances.• Severe conditions (e.g., dehydration, hypoxia, hyperglycemic-hyperosmolar state, hypotension or shock, ketoacidosis).• Interference from other sugars (e.g., maltose intravenous solutions)

1279

1280

Appendix 2. Special 510(k)s and SMBG Devices

What is a special 510(k) and how does it apply to your blood glucose meter submission?

A special 510(k) submission is an alternative to the traditional method of demonstrating substantial equivalence for certain modifications that do not alter the intended use or fundamental scientific technology of the device. For such modifications, the Agency believes that the rigorous design control procedure requirements outlined in the Quality System Regulation (QS reg) [See 21 CFR part 820] produce highly reliable results that can form, in addition to the other 510(k) content requirements, a basis for the substantial equivalence determination.

As such, under the special 510(k) option, a manufacturer who is intending to modify his/her own legally marketed device will perform and present the risk analysis and the necessary verification and validation activities to demonstrate that the design outputs of the modified device meet the design input requirements. Once the manufacturer has ensured the satisfactory completion of this process, a "Special 510(k): Device Modification" may be submitted.

Eligibility for a Special 510(k)

To determine whether a modified SMBG device is eligible to be submitted as a special 510(k), you should consult the FDA Guidance Document entitled "The New 510(k) Paradigm - Alternate Approaches to Demonstrating Substantial Equivalence in Premarket Notifications - Final Guidance" which can be found at:

www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm080187.htm. Sponsors should also consult the document "How to Prepare a Special 510(k)" at: <http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/PremarketSubmissions/PremarketNotification510k/ucm134573.htm>

As noted above, a special 510(k) is appropriate where the candidate device is a modification of a sponsor's own legally marketed device, which would serve as the predicate for the modified device. This usually means that the candidate device and predicate device are part of the same device design file. The existence of *similarities* between the predicate device A and candidate device B does not by itself necessarily mean that device B is a modification of device A.

FDA believes that to ensure the success of the Special 510(k) option, there should be a common understanding of the types of device modifications that may gain marketing clearance by this path. In this vein, it is critical that Industry and Agency staff can easily determine whether a modification is appropriate for submission as a Special 510(k). To optimize the chance that a Special 510(k) will be accepted for review, sponsors should evaluate each modification to ensure that the device modification does not: (1) affect the intended use or (2) alter the fundamental scientific technology of the device.

Contains Nonbinding Recommendations
Draft - Not for Implementation

1323 Based on FDA's experience with blood glucose meters, we can offer the following list of
1324 modifications that may or may not be eligible for review as a special 510(k). This list is not
1325 intended to be all-inclusive.

1326

1327 **Modifications that are generally eligible for a special 510(k):**

1328

- 1329 • Minor changes in user interface
- 1330 • Addition of wired data transfer capability (e.g., adding the ability to transmit glucose
1331 results to a personal computer)
- 1332 • Change in memory capabilities (e.g., adding the ability to store additional results)
- 1333 • Elimination of strip coding requirements through a restriction of test strip lot release
1334 criteria
- 1335 • Addition of a voice (speaking) feature if the device is not intended for visually
1336 impaired users

1337

1338 **Modifications that are generally NOT eligible for a special 510(k):**

1339

- 1340 • Significant change in the sample volume applied to the glucose test strip
- 1341 • Addition of alternate sampling sites (e.g., adding the palm in addition to the fingertip)
- 1342 • Addition of sample matrices (e.g., adding venous blood in addition to capillary blood)
- 1343 • Change to the measuring algorithm used to calculate a glucose concentration
- 1344 • Change in enzyme used in the chemical reaction (e.g. from glucose dehydrogenase to
1345 glucose oxidase)
- 1346 • Use of a test strip cleared for meter A for use on separately cleared meter B
- 1347 • Any modification that affects the intended use of the device
- 1348 • Any change in fundamental scientific technology

1349

1350 We recommend that you contact OIR to discuss any specific questions you have regarding
1351 your SMBG device's eligibility to be submitted as a special 510(k).

1352